Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2024; 12(20): 4405-4411
Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4405
Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4405
Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report
Xing-Zu Ji, Zhong-Da Liu, Quan Li, Xiao-Jing Liu, Min-Hua Zhou, Department of Respiratory and Critical Care Medicine, Lishui Hospital of Traditional Chinese Medicine, Lishui 323000, Zhejiang Province, China
Yi-Ping Ye, Traditional Chinese Medicine Oncology, Lishui Hospital of Traditional Chinese Medicine, Lishui 323000, Zhejiang Province, China
Yi Jin, Department of Emergency Medicine, Lishui People's Hospital, Lishui 323000, Zhejiang Province, China
Co-first authors: Xing-Zu Ji and Zhong-Da Liu.
Author contributions: Ji XZ designed the study; Liu ZD, Ye YP, Li Q, Liu XJ, and Zhou MH performed the data collection and analyzed the data; Jin Y wrote the manuscript; All authors reviewed the manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and all accompanying images.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi Jin, BMed, Attending Doctor, Department of Emergency Medicine, Lishui People's Hospital, No. 15 Mass Street, Liandu District, Lishui 323000, Zhejiang Province, China. 15990421805@163.com
Received: April 7, 2024
Revised: May 23, 2024
Accepted: June 3, 2024
Published online: July 16, 2024
Processing time: 83 Days and 13.7 Hours
Revised: May 23, 2024
Accepted: June 3, 2024
Published online: July 16, 2024
Processing time: 83 Days and 13.7 Hours
Core Tip
Core Tip: Patients inevitably encounter drug resistance after receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. EGFR-TKIs resistance included primary and acquired. Pathological transformation is one of mechanism of acquired resistance in EGFR-TKIs, with squamous cell carcinoma (SCC) transformation being relatively rare. This results provide more detailed results of the patients’ diagnosis and treatment process, alongside a review of literature on SCC transformation after EGFR-TKIs treatment for lung adenocarcinoma.